Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06617182

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury: a Single-center, Open-label, Randomized Controlled Study

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Yongquan Shi · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. Studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. Therefore, The investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.

Detailed description

Screening: This phase will not last longer than one week, and the subject will be assessed for eligibility after signing the informed consent form. Treatment: Subjects were randomly assigned to three different treatment groups for 8 weeks. Follow-up: The subjects' defecation status was recorded every day during treatment, telephone follow-up was conducted every two weeks, and laboratory indicators (including blood routine, stool routine, etc.) were tested every four weeks. The test was terminated one week after treatment and the improvement of subjects' stool blood was assessed.

Conditions

Interventions

TypeNameDescription
DRUGThalidomidePatients in thalidomide group took thalidomide orally at a dose of 100mg once a day for 8 weeks.
DRUGGlutamineIn the glutamine group, two capsules of glutamine were taken orally 3 times a day for 8 weeks.
DRUGThalidomide+GlutaminePatients in thalidomide combined with glutamine group took thalidomide orally at a dose of 100mg once a day and two capsules of glutamine were taken orally 3 times a day for 8 weeks.

Timeline

Start date
2024-09-30
Primary completion
2028-10-01
Completion
2028-11-01
First posted
2024-09-27
Last updated
2026-03-27

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06617182. Inclusion in this directory is not an endorsement.